News / Korea / yonhap_finance
NeoImmuneTech Hits Daily Limit for Second Straight Day on US Licensing Deal
Health Technology · Biotechnology · yonhap_finance · 2026-08-21
950220
NeoImmuneTech shares surged to the daily limit for two consecutive days following a licensing agreement with US-based Tolerance Bio for its NT-I7 therapy.
What Happened
Licensing Agreement: NeoImmuneTech has signed a deal to transfer exclusive development and commercialization rights for its immunotherapy agent, NT-I7, to the US biotech firm Tolerance Bio. This marks the company's first major licensing agreement since its KOSDAQ debut.
Therapeutic Focus: NT-I7 acts as a T-cell amplifier designed to eliminate cancer and infected cells. The partnership specifically targets indications related to thymic dysfunction, including immune reconstitution for HIV patients.
Deal Structure: The agreement is valued at approximately 367 billion KRW in milestone payments, alongside a 4% equity stake in Tolerance Bio. The company will also receive tiered royalties based on annual net sales generated from the product.
Market Reaction: The announcement triggered strong investor demand, driving the stock to the daily upper limit for two consecutive trading sessions. Shares closed at 2,850 KRW on the 21st as the market reacted positively to the news.